Svb Leerink Reiterates Outperform Rating for Arcus Biosciences (RCUS)

Arcus Biosciences (NYSE:RCUS)‘s stock had its “outperform” rating reiterated by investment analysts at Svb Leerink in a research note issued to investors on Friday, Zacks.com reports.

A number of other equities research analysts have also weighed in on the stock. BTIG Research began coverage on shares of Arcus Biosciences in a report on Monday, March 18th. They set a “buy” rating and a $20.00 price target for the company. Zacks Investment Research raised shares of Arcus Biosciences from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a report on Thursday, March 7th.

RCUS opened at $10.53 on Friday. The firm has a market cap of $468.73 million, a P/E ratio of -7.36 and a beta of 1.18. Arcus Biosciences has a twelve month low of $8.57 and a twelve month high of $17.50.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.07). The firm had revenue of $1.75 million for the quarter, compared to analyst estimates of $1.25 million. Arcus Biosciences had a negative net margin of 613.46% and a negative return on equity of 22.18%. Equities analysts anticipate that Arcus Biosciences will post -1.67 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can bought a new position in Arcus Biosciences during the 4th quarter valued at $51,000. Federated Investors Inc. PA bought a new position in Arcus Biosciences during the 3rd quarter valued at $55,000. Legal & General Group Plc boosted its stake in Arcus Biosciences by 311.5% during the 4th quarter. Legal & General Group Plc now owns 5,818 shares of the company’s stock valued at $62,000 after acquiring an additional 4,404 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in Arcus Biosciences by 1,931.5% during the 1st quarter. BNP Paribas Arbitrage SA now owns 6,521 shares of the company’s stock valued at $81,000 after acquiring an additional 6,200 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Arcus Biosciences during the 1st quarter valued at $110,000. 49.14% of the stock is owned by institutional investors and hedge funds.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.

See Also: Index Funds

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.